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Pluchea indica (L.) Less. (P. indica) tea has been used for a health-promoting drink, especially in Southeast Asia. ,e effect of P.
indica tea (PIT) on amelioration of hyperglycemia; dyslipidemia that was total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-
cholesterol (HDL-C), and triglyceride (TG); and obesity in high fat diet-induced (HFD) mice was investigated. Oral glucose
tolerance test (OGTT) displayed that PITat 400 and 600mg/kg orally ameliorated hyperglycemia with a dose-dependent manner
compared to the untreated group. Moreover, PIT at these dosages exhibited significantly lower TC, LDL-C, TG, and perigonadal
fat weight in HFD treated mice compared to HFDmice (P< 0.05) with a dose-dependent manner. In contrast, HDL-C was higher
than in the HFD group, but not a significant difference (P> 0.05). ,e PIT chemical analysis results demonstrated that PIT
contained total phenolic content (TPC), total flavonoid content (TFC), 4-O-caffeoylquinic acid (4-CQ), 5-O-caffeoylquinic acid
(5-CQ), 3,4-O-dicaffeoylquinic acid (3,4-CQ), 3,5-O-dicaffeoylquinic acid (3,5-CQ), 4,5-O-dicaffeoylquinic acid (4,5-CQ), beta-
caryophyllene, and gamma-gurjunene that may play an important role in inhibiting hyperlipidemia and hyperglycemia. Also,
histological analysis expressed that the mean area and amount of perigonadal fat adipocytes of PIT treated groups were sig-
nificantly lower and higher than the HFD group (P< 0.05), respectively. ,e toxicity test of PITat 600mg/kg/day in mice showed
that serum creatinine, alanine transaminase (ALT), alkaline phosphatase (ALP), and complete blood count (CBC) levels of HFD
and PIT treated groups were not significantly different compared to the normal control diet group (NCD) (P> 0.05).,ese results
suggest that PITdoes not become toxic to the kidney, liver, and blood. In conclusion, PIT has the potential to develop into healthy
food supplement or medicine for the prevention and treatment of hyperglycemic, hyperlipidemic, and obese patients.
1. Introduction
,e incidence of diabetes mellitus, dyslipidemia, and obesity
is currently increasing at a dramatic rate throughout the
world. In 2015, an estimated 415 million people had type 2
diabetes worldwide, which is an equal rate compared among
more than 90% of women andmen [1]. Diabetes mellitus is a
group of metabolic disorders characterized by hyperglyce-
mia and insufficiency of secretion or action of endogenous
insulin [2–4]. Diabetes is associated with long-term damage,
dysfunction, and failure of different organs such as eyes,
kidneys, nerves, heart, and blood vessels [5]. Diabetes
ketoacidosis may occur in acute complications when blood
sugar is higher, and it can become coma or death [6].
Moreover, diabetes mellitus is associated with dyslipidemia,
which is one of the major risks for the provocation of
cardiovascular disease (CVD) [7], and atherosclerosis which
is a significant cause of morbidity and mortality worldwide
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[8]. Dyslipidemia is characterized by an abnormal amount of
lipids, such as triglyceride, LDL-cholesterol, total choles-
terol, and HDL-cholesterol in the blood [9]. Furthermore,
diabetes and dyslipidemia are practically relevant to obesity
[10–12]. Obesity is defined as abnormal or excessive fat
accumulation caused by an imbalance of energy intake and
expenditure. Obesity causes significant increase in the risk of
morbidity and mortality [13]. Obesity can be treated by
suppressing food intake, stimulating energy expenditure by
regulating lipid metabolism, and reducing fat digestion and
absorption [14].
Nowadays, current conventional medications for blood
sugar and lipids modulating are widely used, but some drugs
have limited efficacies and critical adverse effects, such as
rhabdomyolysis from HMG-CoA reductase inhibitors [15]
and hypoglycemia from insulin and sulfonylurea [16, 17].
,erefore, the use of herbal supplements or alternative
medicines, which may have minor adverse effects and are
often cheaper and easily consumable [18], has become in-
creasingly popular during the last decade [19].
P. indica (Asteraceae) leaves have been used for a health-
promoting drink [20] and in folk medicine, especially in
Southeast Asia, including ,ailand. ,e plant has various
biological activities, such as a diuretic, and anti-
hyperglycemic activities of its methanolic extract [21, 22].
Moreover, PIT also had antiadipogenesis in 3T3-L1 cell and
lipase enzyme inhibition effects [23]. ,erefore, PIT has the
potential to develop to be a health-promoting drink and
herbal medicine for hyperglycemia and dyslipidemia
prevention.
,is study aimed to investigate the effect of PIT on
hyperglycemia and dyslipidemia prevention in mice. Be-
sides, the antiobesity and toxicity of this tea inmice were also
studied.
2. Materials and Methods
2.1. PlantMaterials. PITwas supported and prepared by,e
Crystal Biotechnology Co., ,ailand, and Suranaree Uni-
versity of Technology. In brief, fresh herbs of P. indica were
collected from Nakhon Ratchasima and northeast region of
,ailand. ,e plant specimen was authenticated by Dr. Paul
J Grote, and the identification was made in comparison with
the voucher specimen (BKF 194428) and deposited at Forest
Herbarium, National Park, Wildlife, and Plant Conservation
Department, Ministry of Natural Resources and Environ-
ment, ,ailand. ,ese plants were washed thoroughly; then
they were ground and dried in an oven at 80°C for 120min.
Tea was freshly prepared daily by brewing 3g dried extract in
80°C distilled water 100mL for 5min and was filtered by
Whatman No. 1 filter paper to complete 3%°(w/v) PIT
extract.
2.2. Chemicals andReagents. A total of 10% neutral buffered
formalin solution, sucrose, D-(+)-glucose, xylenes, Mayer’s
hematoxylin solution, eosin Y solution, simvastatin, and
glibenclamide were obtained from Sigma-Aldrich Chemical
Co. (St. Louis, MO, USA) and 60% fat calories mouse diet or
high fat diet (% composition: protein 20%, fat 36%, fiber 0%,
ash 3.5%, moisture< 10%, and carbohydrate 35.7%) was
purchased from Bio-Serv (Frenchtown, NJ, USA). 5-O-
Caffeoylquinic acid (5-CQ), 4,5-O-dicaffeoylquinic acid
(4,5-CQ), 4-O-caffeoylquinic acid (4-CQ), 3,5-O-dicaf-
feoylquinic acid (3,5-CQ), and 3,4-O-dicaffeoylquinic acid
(3,4-CQ) were purchased from Chengdu Biopurify Phyto-
chemicals Ltd., (Sichuan, China). All reagents used were
analytical grade.
2.3. Total Phenolic Content (TPC), Total Flavonoid Content
(TFC), Liquid Chromatography-Mass Spectrometry/Mass
Spectrometry (LC-MS/MS) Analysis, and Gas Chromatogra-
phy-Mass Spectrometry (GC-MS) Analysis. ,e active
chemical compounds in PIT were analyzed by TPC, TFC,
LC-MS/MS, and GC-MS. Total phenolic content was
measured by the Folin–Ciocalteu assay following Singleton
and Rupasinghe et al.’s method [24]. Similarly, an alu-
minium chloride colorimetric assay was performed to de-
termine total flavonoid content [25]. Furthermore, the major
chemical compounds of the PITwere analyzed using the LC-
MS/MS instrument, as previously reported by Sir-
ichaiwetchakoon et al. [23]. In brief, ,e LC-MS/MS system
was combined from Agilent HPLC 1290 Infinity and mass
analyzer 6490 Triple Quad LC/MS Agilent Technologies,
with electrospray ionization (ESI) source system, consisting
of an autosampler, a binary pump, and vacuum degasser.
Agilent ZORBAX Rapid Resolution High Definition
(RRHD) SB-C18, 2.1mm id× 150mm (1.8 µm), was used for
chromatographic separation and mobile phase system used
solvents A and B, which consisted of 1% formic acid in water
and in acetonitrile, respectively. A combination of both
solvents in LC system was set at a ratio of solvent A : solvent
B, 100 : 0 with gradient elution—from 30% solvent B at
10min and 100% solvent B at 30min at a flow-rate of
0.2mL·min−1. ,e sample injection volume was set at 5 µL,
and the temperature was maintained at 25°C. ,e solutions
of 4-CQ, 5-CQ, 3,4-CQ, 3,5-CQ, and 4,5-CQ were used as
standards. Moreover, the GC-MS analysis was performed by
using Bruker Gas Chromatography Model 450GC equipped
with Bruker 320MS. Analysts were separated on a column:
Rtx-5MS capillary column (30m× 0.25mm, fused silica
0.25 µm). ,e following temperature program was set up at
50–250°C with 2 increasing steps. Oven initial temperature
was 50°C for 1min, then increased to 120°C at a rate of 5°C/
min, and held at the 120°C for 40min. In the final step, the
column temperature was increased up to 250°C at a rate of
3°C/min. ,e total running time was 98.33min, and the
carrier gas was helium (1mL·min−1). Injector volume was
1 μl, and injector temperatures were held at 250°C. Com-
pound identification was done by comparing it with NIST
Mass Spectral Library.
2.4. Animals and Experimental Design. Ninety adult male
mice (ICR mouse), aged about 8 weeks and weighing
30–40 g, were used in these experiments. ,ese mice were
divided into 2 groups.,e first group was 40 mice for an oral
glucose tolerance test. ,e second group was 50 mice for
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lipid profile and toxicological examination. All mice were
obtained from the Animal Care Building, Suranaree Uni-
versity of Technology, Nakhon Ratchasima, ,ailand. ,e
experimental protocol was approved in accordance with a
guideline for the care and use of laboratory animals by the
animal care and use committee (ACUC), Suranaree Uni-
versity of Technology. ,e approval number of institutional
authorities on the care and use of animals was 7/2560. Mice
were housed in a light, humidity, and temperature controlled
room (light on 12 h/day, temperature 25± 0.5°C, and the
moisture 40%± 2%) at the animal care building at Suranaree
University of Technology, Nakhon Ratchasima, ,ailand.
,e mice had free access to food pellets and water except
when fasted before blood collection and necropsy.
2.5. AnOral Glucose Tolerance Test (OGTT). An oral glucose
tolerance test was performed to measure how well the body
can process a more considerable amount of sugar. ,is test
was carried out using the method described by Clemmensen
et al. with slight modifications [26]. After acclimation for 2
weeks, mice were randomly divided into 4 groups (n� 10).
,en, fasting for 16 h, blood from all mice was collected for
measuring blood glucose before each group received single
oral administration of D-glucose at 2 g/kg body weight plus
the following test agent. ,e control group (CON) was fed
water. ,e positive control group was fed glibenclamide at
10mg/kg/day (GLI).,e P. indica tea at a low dose (PIL) and
high dose (PIH) treated groups were fed PIT at 400 and
600mg/kg/day, respectively. Blood glucose was measured by
an Accu-Chek glucometer (Roche, Basel, Switzerland) using
Accu-Chek test strips at 0, 15, 30, 60, and 120min that
initiated from the oral glucose administration.
2.6. #e Lipid Profile and Toxicological Testing. ,e effect of
PIT on serum lipid profile and toxicity experiments were
performed as previously described by Vaghasiya et al. and
Kuo et al. with little modifications [27, 28].,e flow diagram
of the experimental design is shown in Figure 1. Shortly,
mice were randomly divided into 5 groups (n� 10). ,e
normal control diet group (NCD) was fed a normal mouse
diet and water. ,e high fat diet group (HFD) was fed a high
fat diet and water. ,e positive control group, simvastatin
(SIM), was fed a high fat diet and simvastatin at 20mg/kg/
day. ,e PITat a low dose (PIL) and high dose (PIH) treated
groups were fed high fat diet and PIT at 400 and 600mg/kg/
day, respectively. ,e experimentation was performed for 4
weeks. At the end of the treatment period, all mice were
sacrificed under thiopental sodium anesthesia and subjected
to necropsy. ,e blood was collected to analyze total cho-
lesterol (TC), LDL-cholesterol (LDL-C), triglyceride (TG),
and HDL-cholesterol (HDL-C). Besides, creatinine, alanine
transaminase (ALT), alkaline phosphatase (ALP), and
complete blood count (CBC) were measured for toxicity
testing.
2.7. Measurement of Body Weight, Food Intake, Relative
Organ, and Perigonadal Fat Weight. ,e body weight, food
intake, relative organ, and perigonadal fat weight were
measured using Han et al.’s method [29]. In brief, the body
weight of all mice was measured every week. Food intake was
assessed daily, and the average daily food intake was cal-
culated. At the end of the experiment, mice were sacrificed.
,en, the liver, heart, kidney, lung, spleen, and perigonadal
fat were collected, and weights were measured. ,e relative
organ and perigonadal fat weight per 100 g of total body
weight of each mouse were calculated as follows:
relative organweight(g/100 g body weight) �
weight of mouse organ(g) × 100
mouse body weight(g)
. (1)
2.8. Histological Analysis. ,e perigonadal fat pad histo-
logical analysis was performed as previously described by Kim
et al. with little modifications [30]. In brief, after treatment for
4 weeks, all mice were sacrificed. Next, the perigonadal fat pad
was collected and preserved in 10% (w/v) neutral phosphate
buffer formaldehyde. ,e tissues were fixed in 10% neutral
buffered formalin, embedded in paraffin, and cut with a
microtome at 5 µm. ,e sectioned tissues were placed in
xylenes and rehydrated through serial alcohol gradients
(100%, 95%, 90%, 80%, 70%, and 50%, 2min each). Hema-
toxylin and eosin were used for staining. ,e histopathology
of the tissue slide was examined under a light microscope.,e
number of adipocytes per each field and the central area of
each adipocyte were counted and analyzed.
2.9. Statistical Analysis. All data were presented as the
mean± SEM.,e statistically significant differences between
groups of food intake, mouse weight, blood toxicity testing,
epididymal fat pads, and relative organ weight were analyzed
by ANOVA with a Tukey’s HSD post hoc test. Paired
Student’s t-test was used to compare the differences in serum
lipid profile (TC, LDL, HDL, and TG) analysis between pre-
and posttreatment groups. ,en, a significant difference
between each group was compared using ANCOVA. Tukey’s
HSD post hoc test at P< 0.05, which means sharing the
different superscript letters, was also considered a statisti-
cally significant difference between each group [31, 32].
3. Results
3.1. Total Phenolic Content (TPC), Total Flavonoid Content
(TFC), LC-MS/MS Analysis, and GC-MS Analysis. ,e TPC
results indicated that the PIT contained 107.95± 4.87mg
GAE/g of dry weight of total phenolic content. Moreover,
TFC analyzed demonstrated that PIT was comprised of
95.33± 0.48mg CE/g of the dry weight of total flavonoid
content. ,e MRM transition chromatograms at m/z
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353⟶191.0 displayed that 4-CQ and 5-CQ were detected
in the PIT extract. Furthermore, 3,4-CQ, 3,5-CQ, and 4,5-
CQ were discovered at m/z 515⟶ 353 (Table 1). ,ese
results are virtually the same quantity as the previous result
of Sirichaiwetchakoon et al. [23]. ,e highest of these
compounds was 3,5-CQ and it was found that a PIT con-
centration of 1500 µg·mL−1 consisted of 3,5-CQ at
169.93 µg·mL−1. ,e GC-MS analysis of the PIT is presented
in Figure 2 and Table 2. ,e results showed that the PIT
contained 31 compounds, and the abundant primary
compounds were beta-caryophyllene and gamma-gurjunene
with %area at 33.56% and 25.90%, respectively.
3.2. Oral Glucose Tolerance Test (OGTT). Antihyperglycemic
effects of PITwere evaluated in normal mice. Dosages of PIT
at 400 and 600mg/kg were compared with glibenclamide
10mg/kg, which was used as a positive control. ,e blood
glucose level was measured at 0, 15, 30, 60, and 120min,
respectively. Figure 3 showed that the blood glucose level of
PIL, PIH, and GLI groups was significantly lower than the
untreated group from 15 to 60min (P< 0.05). At 30min, the
high dose of PIT (PIH) expressed a significantly lower blood
glucose level compared to GLI (P< 0.05). Besides, the blood
sugar levels of PIH and GLI groups were considerably lower
than those of CON and PIL at 120min (P< 0.05).
3.3. Effect of PIT on Serum Lipid Profiles. ,e effect of PIT
on serum lipid profile had been revealed. ,e TC, LDL-C,
and TG levels of the HFD group were significantly higher
than the NCD group (P< 0.05; Figures 4(a), 4(b), and 4(d)).
,e serum TC levels in the PIL, PIH, and SIM groups
were 257.40± 21.39mg·dL−1, 242.50± 12.82mg·dL−1, and
237.50± 12.05mg·dL−1, respectively, significantly lower than
the HFD which was 306.80± 27.37mg·dL−1 at week 4
(P< 0.05; Figure 4(a)). Furthermore, Figure 4(b) showed the
serum LDL-C levels of PIL (53.16± 10.62mg·dL−1), PIH
(47.43± 4.17mg·dL−1), and SIM (42.48± 2.54mg·dL−1) were
significantly lower than the HFD (73.12± 6.83mg·dL−1) at
week 4 (P< 0.05). Interestingly, the serumTG level of the PIH
treated group (147.25± 9.13mg·dL−1) was significantly lower
than the positive control (SIM, 180.75± 19.30mg·dL−1) and
HFD groups (240.60± 27.02mg·dL−1) (P< 0.05), while there
was no significant difference from the PIL group
(157.45± 10.15mg·dL−1) (Figure 4(d)). ,e result of the se-
rumHDL-C level exhibited that theHDL-C levels at week 4 of
PIL and PIH groups were higher than the HFD group, but it
was not a significant difference (P> 0.05, Figure 4(c)). Also,
the HDL-C level of the SIM group was significantly higher
than the HFD group (P< 0.05).
3.4. Effect of PIT on Food Intake and Body Weight. ,e av-
erage food intake of mice was investigated. Figure 5 shows
the effect of PIL and PIH on food intake compared to NCD,
HFD, and SIM groups. PIL and PIH showed significantly
lower food intake than the HFD group from the first week
until the end of the experiment (P< 0.05).
,e body weight of mice in all groups was measured
every week. ,e result was consistent with the average
food intake result (Figure 6). ,e mouse’s weight of the
HFD group was significantly heavier than the NCD group
at week 4 (P< 0.05, Figure 6). Apart from this, the HFD
group exhibited TC, TG, and DL-C significantly higher
than the NCD group (P< 0.05, Figure 4). For this reason,
these findings provide evidence that these HFD mice are
obese. At week 2, PIH showed significantly lower body
weight than the HFD, NCD, and SIM group (P< 0.05),
but not a significant difference from PIL (P> 0.05).
Moreover, the body weight of the PIL group was sig-
nificantly lower than the HFD group from weeks 3 to 4
(P< 0.05).
3.5.Effect ofPITonRelativeOrganWeight. ,e relative organ
weights of liver, heart, kidney, lung, and spleen of mice after
feeding with HFD and HFD plus PIL or PIH or SIM are
Day 0
Mice weighing
Blood collecting for
lipid and toxicity 
testing
- Sacrificed
Day 28Day 21Day 14Day 7
Mice weighingMice weighingMice weighingMice weighing
Drug administration
Daily food intake measuring
Figure 1: Schematic drawing of the experimental protocol. (a) Lipid and toxicity analysis. (b) Relative organ analysis. (c) Perigonadal fat
analysis.
Table 1: A main chemical constituent of PIT that was analyzed by
LC-MS/MS analysis.
Main chemical constituent Detection
4-O-Caffeoylquinic acid (4-CQ) +
5-O-Caffeoylquinic acid (5-CQ) +
3,4-O-Dicaffeoylquinic acid (3,4-CQ) +
3,5-O-Dicaffeoylquinic acid (3,5-CQ) +
4,5-O-Dicaffeoylquinic acid (4,5-CQ) +
+ means those compounds have been detected.
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shown in Table 3. ,e relative weights of the liver, heart,
kidney, lung, and spleen of PIL, PIH, and SIM groups were
not significantly different from the NCD and HFD groups
(P> 0.05).
3.6. Effect of PIT on Biochemical Parameters in Mice Serum.
,e serum creatinine, ALT, ALP, and the CBC were mea-
sured to investigate the toxicity of PIT on the kidney, liver,
and blood. Figure 7(a) showed that the serum creatinine
levels of PIL, PIH, and SIM groups were not significantly
different compared to NCD and HFD groups (P> 0.05).
,ese results suggest that PIL, PIH, and SIM may not be
toxic to the kidney. Besides, the serum ALT and ALP of the
PIL, PIH, and SIM groups were not significantly different
from NCD and HFD groups (P> 0.05, Figures 7(b) and
7(c)). ,ese results imply that PIL, PIH, and SIM should not
be toxic to the liver. ,e CBC testing provides essential
information regarding three major types of cells in the blood:
RBC count, WBC count, and platelets. Figures 8(a)–8(c)
display RBC count, WBC count, and platelets, respectively.
,ese results showed that the CBC of all treated groups was
not significantly different compared to NCD and HFD
groups (P> 0.05).
M
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Figure 2: GC-MS chromatogram of compounds in PIT.
Table 2: Compounds in PIT that was analyzed by GC-MS analysis.
Compounds RT (min) Area (%)
Methane, thiobis- 1.555 4.89
2-Propenoic acid 2.600 4.05
Hexanal 3.402 0.09
Dimethyl sulfoxide 4.005 1.14
2,4-Heptadienal, (E,E)- 8.111 0.28
3,5-Octadien-2-one, (E,E)- 9.766 0.32
2-Heptanone, 6-methyl- 10.825 0.21
2,5-Furandione, 3-(1,1-dimethylethyl)- 12.032 0.26
Decane 13.354 0.09
Beta-cyclocitral 14.018 0.07
2H-2,4a-Ethanonaphthalene, 1,3,4,5,6,7-hexahydro- 17.240 4.10
Gamma-gurjunene 18.033 25.90
Alpha-cubebene 18.183 0.18
Aromadendrene, dehydro- 18.517 0.71
(+)-Cyclosativene 18.985 0.33
Copaene 19.378 5.14
Alpha-patchoulene 19.629 1.04
Beta-cubebene 20.035 0.10
Dodecane 20.495 0.09
Beta-caryophyllene 21.755 33.56
Beta-selinene 23.706 1.86
Beta-ionone 26.190 0.61
Drimenol 29.204 0.74
Delta-cadinene 29.464 0.26
2(4H)-Benzofuranone, 5,6,7,7a-tetrahydro-4,4,7a-trimethyl- 29.687 0.54
Caryophyllene oxide 32.180 2.08
1,5,5,8-Tetramethyl-12-oxabicyclo[9.1.0]dodeca-3,7-diene 32.858 1.78
4,11,11-Trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene 34.828 0.75
Caryophyllene oxide 35.706 4.04
Tetracyclo[6.3.2.0(2,5).0(1,8)]tridecan-9-ol,4,4-dimethyl- 43.841 4.74
Isopropyl palmitate 78.750 0.05
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3.7. Effect of PIT on Perigonadal Fat. ,e perigonadal fat
weight result is demonstrated in Figure 9. ,e perigonadal
fat weights of PIL and PIH groups were significantly lower
than the HFD group (P< 0.05), but not a significant
difference from NCD and SIM groups (P> 0.05). ,e H&E
staining of perigonadal fat photographs is shown in
Figure 10. ,e adipocytes size (area) and the number of
adipocytes per field are demonstrated in Figures 11(a) and
11(b), respectively. ,e mean area and the number per
field of adipocytes of PIL and PIH groups were signifi-
cantly lower and higher than the HFD group (P< 0.05),
respectively. However, these parameters were not sig-
nificant differences compared to NCD and SIM groups
(P> 0.05).
4. Discussion
Obesity is occurring by an imbalance between energy
consumption and expenditure. Obesity is a major risk factor
of various diseases, especially type 2 diabetes, dyslipidemia,
and cardiovascular disease [33, 34].
High fat diet feeding in mice has been widely used as a
model for dyslipidemia studies of antidyslipidemia evalua-
tion because it can induce obesity and dyslipidemia. PIT has
been used for a health-promoting drink [20] that has the
potential to protect hyperglycemia, obesity, and
dyslipidemia.
,e results from this study showed antihyperglycemic
effect of PIT using an oral glucose tolerance test compared
with conventional medicine glibenclamide. ,e results
showed that PIT at 400 and 600mg/kg showed a significant
hypoglycemic effect in mice after feeding with glucose.
Interestingly, PIH reduced the plasma glucose level to
190± 8.84mg·dL−1, which is significantly lower than the
standard drug, glibenclamide, at 30min. ,ese results are in
substantial agreement with Pramanik et al. [21] where the
methanolic extract of P. indica leaves used in normal and
streptozotocin-induced diabetic rats can show hypoglycemic
effect. ,e PITchemical compound from LC-MS/MS results
demonstrated that PIT contained 4-CQ, 5-CQ, 3,4-CQ, 3,5-
CQ, and 4,5-CQ. ,ese results are in substantial agreement
with those of previous reports in that one of the active
ingredients in P. indica (L.) is caffeoylquinic acid derivatives
[20, 23, 35]. ,ese derivatives could inhibit intestinal
maltase, which might have delayed postprandial hypergly-
cemia [35, 36]. Likewise, it had been reported that the
caffeoylquinic acid derivatives, which are contained in this
plant, might have benefits for the treatment of diabetes by
alleviating hyperglycemia. ,is effect is caused by an in-
crease in insulin sensitivity via activation of
AMPK–AS160–GLUT4 pathway in skeletal muscles and
alpha-glucosidase inhibition, which inhibits the formation
of advanced glycation end products (AGEs), and gluco-
neogenesis in the liver [37–41]. Apart from this, the other
main components of PIT from GC-MS analysis were beta-
caryophyllene, which had been reported about anti-
hyperglycemia through enhancing insulin release in diabetic
rats [42, 43], and gamma-gurjunene. ,ese findings lead us
to believe that caffeoylquinic acid derivatives and beta-
caryophyllene from PIT may play an important role in
inhibiting hyperglycemia by intestinal maltase inhibition,
increasing insulin release and sensitivity, or inhibiting alpha-
glucosidase which results in AGEs and gluconeogenesis
inhibition.
Moreover, HFD-fed mice treated with PIT (400 and
600mg/kg daily) had significantly lower TG, TC, and LDL-C
than the HFD group, whereas HDL-C was higher than HFD
group, but not significantly different. ,e effect of PIH and
PIL on lowering mouse weight and lipid profile corre-
sponded with food intake results in that these extracts could
reduce food intake. Furthermore, the extracts could decrease
perigonadal fat pad weight and adipocyte size and increase
the number of adipocytes per field of testing mice. ,ese
results are in substantial agreement with our previous
findings that PIT inhibits lipids and carbohydrate accu-
mulation in adipocytes and interrupts pancreatic lipase
activity [23] that can lead to a decrease in serum lipid profile
and obesity. Moreover, the previous study found that caf-
feoylquinic acid derivatives, which appeared in PIT
[20, 23, 35], could suppress diet-induced body fat accu-
mulation by downregulating SREBP-1c and related mole-
cules in C57BL/6J mice [44]. Nugroho et al. [45] reported
that oral administration of caffeoylquinic acid-rich L.
stenocephala in BuOH fraction form in rat could decrease
the rat body weight to the level of the untreated group and
reduce abdominal fat pad weight. Moreover, the caffeoyl-
quinic acid had been reported to have antihyperlipidemic
mechanism by increasing the expression of PPARalpha and
PPARdelta, suppressing adiponectin, and upregulation of
LPL and AMPK activities [46–48]. Furthermore, it had been
reported that beta-caryophyllene, one of the main compo-
nents in the PIT, could attenuate palmitate-induced lipid
accumulation through AMPK signaling and prevent ath-
erosclerosis in hypercholesterolemic rats [49–52]. ,ese
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Figure 3: Effect of PIT on an oral glucose tolerance test.
CON� control; PIL� PIT at 400mg/kg; PIH�PIT at 600mg/kg;
GLI� glibenclamide at 10mg/kg. Data are expressed as mean-
s± SEM (n� 10). Means with the different superscript letters are
significantly different from each other (Tukey’s HSD test, P< 0.05).
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pieces of evidence lead us to believe that PIT may have an
antidyslipidemia effect because of increasing the expression
of PPARalpha and PPARdelta, suppressing adiponectin, and
the upregulation of LPL and AMPK activities.
,e toxicity results of PIT on relative organ weight and
biochemical parameters revealed that the relative weights of
liver, heart, kidney, lung, and spleen and ALP, ALT, cre-
atinine, RBC, WBC, and platelet of PIT treated groups were
not significant differences from the NCD and HFD groups
(P> 0.05). ,ese results are in substantial agreement with
those of Pramanik et al. [21] that a methanolic extract of P.
indica in the rat was safe to use even at the doses of 3200mg/
kg of body weight orally. Noticeably, the dosages of PIT in
the experiment can be converted to a human dose by a
simple, practical guide for dosage conversion between an-
imals and humans [53]. From the formula, PIT at 400 and
600mg/kg/d in mice are approximately 35.52 and 48.78mg/
kg/d in humans, respectively. ,ese dosages lead us to be-
lieve that PIT would be safe to a human for drinking once
daily for 4 weeks.
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Figure 4: Effect of PITon serum lipid profile. NCD � normal control diet group; HFD � high fat diet group; PIL � PIT at 400mg/kg/d;
PIH �PIT at 600mg/kg/d; SIM � simvastatin at 20mg/kg/d. (a) Serum cholesterol, (b) serum LDL-C, (c) serum TG, and (d) serum
HDL-C. Data are expressed as means ± SEM (n � 10). ,e significant differences between pre- and posttest in each group were
compared using paired Student’s t-test at ∗P< 0.05 and ∗∗P< 0.01. A significant difference between ANCOVA adjusted the posttreated
level in each group, which means sharing the different superscript letters, and was compared using ANCOVA and Tukey’s HSD post
hoc test at P< 0.05.
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Figure 6: Effect of PIT on mouse weight. NCD�Normal control diet group; HFD�High fat diet group; PIL� PIT at 400mg/kg/d;
PIH� PIT at 600mg/kg/d; SIM� simvastatin at 20mg/kg/d. Data are expressed as means± SEM (n� 10). Means with the different su-
perscript letters in the same week are significantly different from each other (Tukey’s HSD test, P< 0.05).
Table 3: Effect of PIT on relative organ weight.
Groups
Relative weight (g/100 g body weight)
Liver Heart Kidney Lung Spleen
NCD 3.66± 0.27a 0.43± 0.04a 1.64± 0.03a 0.57± 0.06a 0.31± 0.02a
HFD 3.80± 0.18a 0.45± 0.01a 1.43± 0.13a 0.51± 0.02a 0.27± 0.07a
PIL 3.96± 0.13a 0.48± 0.02a 1.67± 0.14a 0.57± 0.09a 0.30± 0.03a
PIH 3.93± 0.04a 0.46± 0.01a 1.72± 0.12a 0.63± 0.04a 0.33± 0.05a
SIM 3.63± 0.16a 0.44± 0.02a 1.44± 0.05a 0.54± 0.02a 0.28± 0.02a
NCD�normal control diet group; HFD� high fat diet group; PIL�PITat 400mg/kg/d; PIH�PITat 600mg/kg/d; SIM� simvastatin at 20mg/kg/d. Data are
expressed as means± SEM (n� 10). Means with the same superscript alphabet in the same column are not significantly different from each other (Tukey’s
HSD test, P< 0.05).
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Figure 7: Effect of PIT on biochemical parameters in serum. NCD� normal control diet group; HFD� high fat diet group; PIL�PIT at
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Figure 8: Effect of PIT on complete blood count. NCD� normal control diet group; HFD� high fat diet group; PIL�PIT at 400mg/kg/d;
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Figure 9: Effect of PIT on perigonadal fat weight. NCD�normal control diet group; HFD� high fat diet group; PIL�PIT at 400mg/kg/d;
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5. Conclusions
,ese findings provide evidence that PIT would ameliorate
hyperglycemia and dyslipidemia and reduce weight gain of
high fat diet mice. Furthermore, the results also exhibited the
blood and vital organs’ safety of the PIT. So, PITmight have
the potential to be developed as a healthy food supplement for
antihyperglycemia, antidyslipidemia, and antiobesity. How-
ever, further investigation of the pharmacological activity of
these active ingredients and safety in humans is required.
(a) (b) (c)
(d) (e)
Figure 10: Microscopic imaging of perigonadal fat tissue after Hematoxylin & Eosin staining of samples. (a) Normal control diet group; (b)
high fat diet group; (c) PIT at 400mg/kg/d; (d) PIT at 600mg/kg/d; (e) simvastatin at 20mg/kg/d. Original magnification × 10 (scale
bars� 100 µm).
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Figure 11: Effect of PITon perigonadal fat tissues. NCD� normal control diet group; HFD� high fat diet group; PIL�PITat 400mg/kg/d;
PIH� PIT at 600mg/kg/d; SIM� simvastatin at 20mg/kg/d. (a) Adipocytes size (area) and (b) number of adipocytes per field. Data are
expressed as means± SEM (n� 10). Means with the different superscript letters are significantly different from each other (Tukey’s HSD test,
P< 0.05).
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